News briefing: Axovant faces months of delay on lead Parkinson's gene therapy; Chinese CAR-T biotech nabs $100M
One of Axovant’s top gene therapy prospects for its second act is hitting a roadblock that could push its clinical timelines back by almost a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
